The insulin-like growth factor (IGF) system is a well-studied growth regulatory pathway implicated in breast cancer biology. Clinical trials testing monoclonal antibodies directed against the type I IGF receptor (IGF1R) in combination with estrogen receptor-α (ER) targeting have been completed, but failed to show benefits in patients with endocrine-resistant tumors compared to ER targeting alone. We have previously shown that the closely related insulin receptor (InsR) is expressed in tamoxifen-resistant (TamR) breast cancer cells. Here we examined if inhibition of InsR affected TamR breast cancer cells. InsR function was inhibited by three different mechanisms: InsR short hairpin RNA, a small InsR-blocking peptide, S961 and an InsR monoclonal antibody (mAb). Suppression of InsR function by these methods in TamR cells successfully blocked insulin-mediated signaling, monolayer proliferation, cell cycle progression and anchorage-independent growth. This strategy was not effective in parental cells likely because of the presence of IGFR /InsR hybrid receptors. Downregulation of IGF1R in conjunction with InsR inhibition was more effective in blocking IGF-and insulin-mediated signaling and growth in parental cells compared with single-receptor targeting alone. Our findings show TamR cells were stimulated by InsR and were not sensitive to IGF1R inhibition, whereas in tamoxifen-sensitive parental cancer cells, the presence of both receptors, especially hybrid receptors, allowed cross-reactivity of ligand-mediated activation and growth. To suppress the IGF system, targeting of both IGF1R and InsR is optimal in endocrine-sensitive and -resistant breast cancer.
INTRODUCTION
Approximately 75% of the breast cancer cases express estrogen receptor-α (ER), representing the most prevalent breast cancer subtype. 1 Patients with ER-positive breast cancer can be treated by inhibiting ER function. This strategy has been successful in early stage and advanced breast cancer, 2,3 but a significant proportion of patients never responded to ER inhibition (de novo or primary resistance) or have progression after a prolonged period of therapy (acquired or secondary resistance). 4, 5 Endocrine resistance still poses a key clinical problem. Recently, targeting of mTORC1 and CDK4/6 have been used to treat ER-positive tumors, 6, 7 but there is still a need for additional strategies, aiming to delay or ideally overcome resistance to endocrine therapy.
Insulin-like growth factor (IGF) signaling occurs through multiple receptors including the type I IGF receptor (IGF1R), insulin receptor (InsR) and hybrid IGF1R/InsR. This receptor system has been implicated in cancer development as well as crosstalk with ER, suggesting that it may contribute to the regulation of ER-positive breast cancer. 8, 9 IGF1R is an estrogen regulated gene and enhances ER transcriptional activity, suggesting co-targeting of receptors might be clinical useful. 10, 11 A number of anti-IGF inhibitors including anti-IGF1R monoclonal antibodies (mAbs), tyrosine kinases inhibitors (TKIs) and ligand-neutralizing antibodies were developed primarily to target IGF1R and IGF ligands while leaving InsR unperturbed. 12 Despite the hope that anti-IGF1R targeted therapies would provide clinical benefit in endocrine-resistant breast cancer, we showed that tamoxifenresistant (TamR) cells lacked IGF1R expression. 13 This finding was validated in women with breast cancers-recurrent endocrine treated tumors showed lower level of IGF1R compared with the pre-treated tumors. 14, 15 Thus, it would be unlikely for anti-IGF1R mAbs to have clinical activity in endocrine-resistant cells. These observations likely explain why the results of phase III clinical trials of anti-IGF1R mAbs tested in endocrine-resistant population have been negative. 16 Unlike IGF1R, InsR is not an estrogen regulated gene and its level remained intact in TamR cells. InsR is closely related to IGF1R, sharing 84% similarity within catalytic domain, 45-65% in ligand-binding domain and more than 50% in the overall amino acid sequence. 17 The highly homologous InsR activates almost identical downstream signaling cascades in a ligand-dependent fashion. On the loss of IGF1R function, osteoblasts shifted from IGF-to insulin-mediated growth and differentiation. 18 Downregulation of IGF1R in breast cancer increased sensitivity to insulin. 19 In addition, in a patient, tumor developed an increased InsR gene copy number while being treated with, and eventually becoming resistant to endocrine therapy. 20 Although InsR expression in cancer has been documented for several decades, [21] [22] [23] [24] InsR inhibition has been intentionally avoided because of concern over disrupting glucose homeostasis.
InsR inhibitors have been developed as dual IGF1R/InsR tyrosine kinase inhibitors: BMS-754807 and OSI-906. These two drugs have completed several clinical trials, including a phase II study against ER+ breast cancer resistant to aromatase inhibitors. The trial has completed but the results have not been disclosed (NCT01225172). Early clinical evidence suggests that TKIs are safer than originally anticipated. Although hyperglycemia was evident in patients treated with OSI-906, encouraging disease control was observed in patients. 25, 26 In this study, we determined that InsR signaling serves as a bypass pathway and compensates for the loss of IGF1R in TamR breast cancer cells. We suppressed InsR functions using three different mechanisms in TamR versus parental breast cancer cells. Our data showed that InsR inhibition alone blocked signaling and cell proliferation in TamR cells but not in the parental cells. When anti-IGF1R mAb was given in conjunction with InsR inhibitor, a complete suppression of insulin-stimulated growth in parental cells was observed, suggesting the involvement of hybrid receptors in the mediation of IGF/insulin in breast cancer cells. Thus, dual inhibition of IGF1R and InsR is necessary for optimal suppression of this signaling system.
RESULTS
TamR cells were more sensitive to insulin treatment compared with their parental cells MCF-7L and T47D are ER-positive human breast cancer cell lines and are estrogen sensitive and are inhibited by selective ER modulators such as tamoxifen. We previously generated TamR cells from MCF-7L and T47D and showed reduced IGF1R expression levels and a lack of efficacy of anti-IGF1R monoclonal antibodies in TamR cells. However, AEW541, a dual TKI that targets both IGF1R and InsR was able to inhibit insulin-and IGF-stimulated signaling and growth. 13 To better understand the role of insulin/InsR in TamR cells, we treated MCF-7L, T47D and their TamR cells with increasing concentrations of insulin for 15 min. As measured by AKT, P70S6K and MAPK phosphorylation, insulin signaling stimulated phosphorylation at lower levels of insulin in TamR cells compared with MCF-7L or T47D parental cells ( Figure 1a ). Monolayer growth and soft agar assays showed greater proliferation and colony formation at lower concentrations of insulin in TamR cells compared with their parental cells (Figures 1b and c).
Genetic knockdown of InsR-reduced insulin-regulated signaling and growth in TamR cells, but not in the parental cells Stable InsR knockdown cell lines were generated in MCF-7L, T47D and their TamR cells using lentiviral short hairpin RNA (shRNA). IGF1R level was unaffected in both MCF-7L and T47D parental cells. Compared with control shRNA, shIR#6 was a more efficient knockdown construct than shIR#2 as downregulations of InsR protein and mRNA levels were greater in cells transduced with shIR#6, validated by immunoblotting and quantitative real-time PCR ( Figure S7 ). A reduction of insulin-mediated signaling was measured by IGF1R/InsR, AKT, MAPK, P70S6K and IRS (pY-20) phosphorylation after InsR knockdown in TamR cells especially in shIR#6 TamR cells. Surprisingly, this was not the case in parental cells even though the InsR level was significantly downregulated (Figure 2a ).
To further examine if InsR knockdown affected biological functions, cells were studied by cell cycle analyses, monolayer growth, and anchorage-independent growth assays. Downregulation of InsR abolished insulin-mediated proliferation (Figure 2c ), cell cycle progression (Table 1 ) and anchorage-independent growth (Figure 2d ) in MCF-7L and T47D TamR cells, but not in MCF-7L or T47D parental cells. Re-introduction of recombinant human InsR (hIR) in shIR#2 and shIR#6 transduced MCF-7L TamR cells rescued insulin-mediated signaling (Supplementary Figure S1A ) and cell proliferation (Supplementary Figure S1B) .
In contrast, InsR overexpression in both MCF-7L and TamR cells showed an upregulation of InsR protein level and also insulinmediated phosphorylation of IRS (pY-20), AKT, P70S6K and MAPK (Supplementary Figure S2A ). However, only MCF-7L TamR cells showed a significant increase in cell proliferation (Supplementary Figure S2B ). S961 inhibited insulin-regulated PI3K/MAPK signaling and growth in TamR cells, but not in parental cells S961, a small peptide was synthesized and shown to be a competitive antagonist with a slightly higher affinity to InsR than insulin and partial agonist effects at lower concentrations. 27 S961 has very low affinity for IGF1R. To examine the effect of S961 in endocrine resistance cells, cells were pre-treated with increasing concentrations of S961 before exposing the cells to either IGF-I or insulin. S961 did not inhibit IGF-I or insulin-regulated signaling in MCF-7L and T47D parental cells even at high concentration as shown by IGF1R/InsR, AKT and MAPK phosphorylation (Figure 3a , Supplementary Figure S3A ). Similarly, S961 did not inhibit insulin or IGF-I stimulated cell cycle progression or anchorage-independent growth in parental cells (Figures 3b and c, Supplementary Figure  S4A and Supplementary Table S1 ). Even though agonist effects of S961 have been reported, we did not observe S961-induced signaling or cell proliferation in these breast cancer cells ( Figure 5b ).
In contrast, S961 blocked insulin-regulated signaling even at concentrations as low as 1 nM concentration in TamR cells (Figure 3a and Supplementary Figure S3B ). Similar sensitivity was reflected in anchorage-independent growth assay ( Figure 3b and Supplementary Figure S4B ) and cell cycle analysis (Figure 3c and Supplementary Table S1 ), where 1 nM concentration of S961 fully diminished insulin-stimulated colony formation growth and S-phase induction, respectively, in MCF-7L TamR cells. A higher S961 concentration was needed to fully block insulin-stimulated growth in T47D TamR cells. Since TamR cells lack IGF1R, they do not respond to IGF-I stimulation.
83-7 mAb downregulates InsR, thus inhibiting insulin-stimulated signaling and growth in TamR cells
Monoclonal antibody clone 83-7 (83-7 mAb) binds α-subunit of InsR allosterically without interfering insulin binding 28 and is specific for InsR binding although its functional roles in cells are not well studied. The antibody has been reported to stimulate lipogenesis, inhibit lipolysis and activate receptor kinase by crosslinking receptor molecules. 29 To explore the effect of 83-7 mAb in cancer cells, we pre-treated 83-7 mAb overnight before treating with IGF-I, IGF-II or insulin in MCF-7L, T47D and TamR cells. As shown in Figure 4a , 83-7 mAb did not induce receptor phosphorylation. In contrast, 83-7 mAb downregulated InsR and effectively blocked IGF-II and insulinstimulated IGF1R/InsR, IRS, AKT and MAPK phosphorylation ( Figure 4a ). To study the biological effects of InsR, anchorageindependent growth assays showed that 83-7 mAb effectively inhibited insulin-stimulated colony formation ( Figure 4b ).
Although 83-7mAb caused some InsR downregulation in the parental cells, there was little to minimal inhibitory effect of 83-7 mAb on MCF-7L and T47D parental cells in terms of IGF-I, IGF-II or even insulin-stimulated signaling and anchorage-independent growth ( Figure 4 ).
Inhibition of InsR was not effective in parental breast cancer cells because of the presence of IGF1R/InsR hybrid receptors
To further explore why InsR inhibition was not effective in MCF-7L and T47D parental cells, we used immunoprecipitation (IP) and immunoblotting to examine the ability of these cells to express IGF1R/InsR hybrid receptors. Co-IP studies showed that IGF1R/InsR hybrid receptors are present in MCF-7L and T47D parental cells but not in TamR cells because of their downregulation of IGF1R ( Figure 5a ). As previously shown, S961 was not effective in parental cells. To inhibit IGF1R and hybrid receptors, we used HuEM164 (also known as AVE1642), an anti-IGF1R mAb shown to specifically bind IGF1R and result in its downregulation. 30 In the parental cells, insulin signaling was more completely extinguished by the use of both IGF1R mAb and S961 (Figure 5b and Supplementary Figure S5) .
Similarly, when shIR transduced parental cells was treated with HuEM164, a synergistic inhibitory effect was achieved, as measured by IGF1R/InsR, IRS, AKT and MAPK phosphorylation. Unlike S961, downregulation of InsR by HuEM164, however, was able to only partially block insulin-mediated signaling in parental cells (Figure5c and Supplementary Figure S6 ). The most complete inhibition of ligand signaling was achieved by the combination of shIR#6 and HuEM164.
DISCUSSION
Although the insulin/InsR signaling system is responsible for glucose homeostasis, it is also a cellular growth factor. Metabolic syndrome associated with obesity and type 2 diabetes, both states of relative insulin resistance resulting in hyperinsulinemia are associated with cancer risk. 31 Breast cancer patients who have these conditions are more likely to suffer metastatic disease, disease recurrence and mortality. 32, 33 When a number of anti-IGF1R mAbs trials failed to show benefits in cancer patients, one mechanistic explanation is the presence of InsR acting as a compensatory pathway to IGF1R inhibition and IGF1R loss. 12 Our endocrine-resistant model showed greater sensitivity towards insulin when IGF1R expression level is lacking ( Figure 1 ). Other studies have also shown similar pattern in prostate cancer and pancreatic neuroendocrine tumors in vivo, where InsR induces mitogenic activities and compensates for IGF1R inhibition or resistance to anti-IGF1R. 34, 35 InsR exists in two isoforms: InsR-A and InsR-B because of alternative splicing of exon 11, differing by 12 amino acids. Previous studies have shown that InsR-B tends to be a metabolic receptor expressed in adult muscle, liver and fat. InsR-B binds only insulin at physiological concentrations. In contrast, InsR-A, a predominant isoform during fetal development is commonly expressed in cancer and binds with high affinity to insulin and IGF-II. 36, 37 Upregulation of InsR-A has been reported in breast, ovarian, lung, colon cell lines and/or human tumors and is thought to mediate tumorigenesis and survivor in response to insulin and IGF-II. [38] [39] [40] [41] [42] However, our endocrine-resistant model did not show an increase in InsR-A/InsR-B ratio of mRNA level compared with parental cells (data not shown). To date, antibodies have not been developed that can distinguish between levels of InsR isoforms, thus the exact protein expression of isoforms is uncertain in cells.
In tumors, the data regarding the role of InsR-A are derived from mRNA levels detected by PCR. Additional study is needed to determine if InsR-B has an important role in cancer biology.
In this study, we blocked InsR function by three different techniques: (1) genetic knockdown of InsR using lentiviral shRNA;
(2) competitively blocked of insulin binding to its receptor by S961; and (3) downregulation of InsR without affecting insulin binding by a mAb. These different techniques showed consistent results, inhibiting InsR was effective in the inhibition of insulinregulated signaling and growth in TamR breast cancer cells, but not in parental cells. These data show that insulin signaling is important in endocrine-resistant cells, but less relevant to parental MCF-7L and T47D cells. The presence of IGF1R or hybrid receptors and little of holo-InsR make insulin only a weak mitogen in parental cells. Similar functions of InsR have been described in an ER-negative model of mouse breast cancer. 43 In this system, InsR suppression was necessary to inhibit murine breast cancers in both normal and hyper-insulinemic hosts. The presence of IGF1R/InsR hybrid receptors allows cancer cells to expand their ligand-binding capacity (Figure 5a ). Insulin can still signal through the other available IGF1R heterodimer upon InsR inhibition; likewise, IGF-I may signal through InsR in a hybrid confirmation suggesting single-target inhibition of IGF1R or InsR is not sufficient to suppress hybrid receptor signaling. However in TamR cells, where there is little IGF1R, InsR becomes the predominant receptor driving insulin-(and IGF-II) stimulated growth. Thus, InsR is an important target in TamR cells. Unfortunately, there is no reliable method to quantify the level of hybrid receptors in cells or patient tumors making it difficult to predict response to antibody-based therapy on only examining levels of receptor expression. However, the use of broader range of receptor biochemical inhibition such a TKI may provide a better therapeutic advantage.
The major concern about targeting InsR is the resulting disruption of glucose homeostasis in normal tissues. Hyperglycemia can be managed by metformin, a commonly used drug for type 2 diabetes that reduces hepatic gluconeogenesis, circulating insulin level, and stimulates glucose uptake in muscle independent of insulin. 44, 45 However the ability of metformin to directly affect cancer cell biology outside of modulating serum insulin levels is not understood. Although there are preclinical data suggesting that metformin has little effect in models of non-diabetic rodent models, 46 the clinical benefits of metformin in non-diabetic women with breast cancer awaits reporting of an adjuvant clinical trial where women were assigned to receive metformin or placebo for 5 years after surgical therapy for breast cancer (NCT01101438).
Thus, direct targeting of InsR would be a preferable strategy. Here we show that monoclonal antibodies and a competitive peptide inhibitor have active against InsR, but there could have significant metabolic effects in vivo. As noted the two isoforms of InsR provide a theoretical strategy to only inhibit the cancer associated function of InsR signaling. If InsR-A specific agents could be developed, then this would not perturb the metabolic functions of InsR-B in normal tissues.
In conclusion, we highlighted the role of InsR in breast cancer biology, especially in the context of resistance to endocrine therapies in ER+ breast cancer cells. Thus InsR should not be neglected as a cancer target. Whether InsR inhibition could overcome primary (de novo) endocrine resistance or treat secondary (acquired) resistance, it is not certain. Combination use of metformin may address hyperglycemia condition resulted from InsR inhibition; however, additional efforts at developing InsR-A blocking agents are warranted.
MATERIALS AND METHODS
Cell lines and culture MCF-7L and T47D are human ER-positive breast cancer cell lines. MCF-7L (parental cell line) was kindly provided by C Kent Osborne (Baylor College of Medicine, Houston, TX) and maintained in improved MEM Richter's modification medium (zinc option) supplemented with 5% fetal bovine serum (FBS), and 11.25 nM insulin. MCF-7L karyotyping and gene expression profiling have shown that these cells are consistent with the originally described cell line (data not shown). T47D (parental cell line) was obtained from ATCC (Manassas, VA, USA) and maintained in MEM supplemented with 5% FBS, 1 × nonessential amino acids and 6 ng/ml insulin. MCF-7L TamR and T47D TamR cells were generated as described. 13 MCF-7 L TamR cells were maintained in phenol-red free IMEM (zinc option) supplemented with 11.25 nM insulin, 5% charcoal/dextran-treated FBS and 100 nM 4-OH tamoxifen, while T47D TamR cells were maintained in phenolred free IMEM supplemented with 6 ng/ml insulin, 1 × nonessential amino acids, 5% charcoal/dextran-treated FBS and 100 nM 4-OH tamoxifen. All cells were grown at 37°C in a humidified atmosphere containing 5% CO 2 . All growth media were supplemented with 100 U/ml penicillin and 100 μg/ ml streptomycin and purchased from Gibco (Grand Island, NY, USA).
Reagents
IGF-I, IGF-II and insulin were purchased from Gemini (West Sacramento, CA, USA) and Eli Lily (Indianapolis, IN, USA), respectively. Puromycin solution was purchased from Sigma-Aldrich (St Louis, MO, USA). Geneticin (G418 sulfate) solution was purchased from Life Technologies (Grand Island, NY, USA). Humanized anti-IGF1R mAB HuEM164 was generously provided by Immunogen Inc (Norwood, MA, USA). Anti-InsR mAB, α-subunit clone 83-7 was purchased from EMD Millipore (Temecula, CA, USA). S961 peptide was generously provided by Novo Nordisk (Maaloev, Denmark). 27 Antibodies Antibodies for total IGF1R (#3027), phosphorylated IGF1R tyrosine 1135 (#3918), phosphorylated AKT serine 473 (#9271) and threonine 308 (#9275), total p44/42 MAPK (#9102), phosphorylated p44/42 MAPK (#4376), phosphorylated p70 S6 kinase (#9205) used in immunoblotting were purchased from Cell Signaling Technology (Beverly, MA, USA). Normal mouse IgG (sc-2025), InsR antibody for IP (sc-57342) and InsR antibody for immunoblotting (sc-711) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Horseradish peroxidase-conjugated anti- 
Immunoblotting analysis
Cells were plated at a density of 3 × 10 5 cells in 60 mm diameter dishes and allow to equilibrate overnight. Full medium was replaced with serum-free medium for 24 h. Cells were then treated, washed twice with ice-cold phosphate-buffered saline and lysed with lysis buffer of 50 mM Tris-Cl (pH 7.4), 1% Nonidet P-40, 2 mM EDTA (pH 8.0), 100 mM NaCl, 10 mM sodium orthovanadate and with complete proteases inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA). Lysates were centrifuged at 12 000 g for 30 min at 4°C. Protein concentrations were measured using bicinchoninic acid protein assay reagent kit (Pierce, Rockford, IL, USA). Whole-cell lysates (50 μg) were boiled in 5 × Laemmli loading buffer, separated by 8% SDS-polyacrylamide gel electrophoresis transferred to polyvinylidene difluoride membrane and immunoblotted according to manufacturer guidelines. For Immunoprecipitation (IP), whole-cell lysates were incubated with either anti-InsR antibody or mIgG overnight at 4°C. Protein A/G PLUS-Agarose bead slurry was added into the samples and incubated for 4 h at 4°C. Beads were washed with lysis buffer five times and boiled in 5 × Laemmli loading buffer. Samples were resolved by 8% SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membrane and immunoblotted.
Reverse transcription and quantitative real-time PCR
Cells were seeded at a density of 2 × 10 5 cells in six-well plates in growth media until reaching 80% confluent. Cellular RNA was isolated using TriPure Reagent according to the manufacturer (Roche). For RNA quality verification, a ratio of 260 nm to 280 nm was determined. A total of 1 μg of RNA was reverse transcribed using qScript cDNA synthesis kit (Quanta Biosciences, Gaithersburg, MD, USA), and quantitative PCR was performed using the University SYBR Green Kit according to the manufacturer's protocol (Roche) on an Eppendorf Mastercycler Realplex machine. The relative abundance of InsR mRNA was calculated using cycle threshold values that were derived from a standard curve and normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) level as an internal control. The forward and reverse primers are as followed: InsR 5′-CAA CGTGGTTTTCGTCCCC-3′ and 5′-AGATGACCAGCGACTCCTTG-3′; GAPDH 5′-TGAAGGTCGGAGTCAACGATTTGGT-3′ and 5′-GAAGATGGTGATGGGATT TC-3′.
Monolayer growth assay
Cells were plated at a density of 15 000 cells per well in 24-well plates and allowed to attach overnight. Full media were replaced and starved with serum-free medium for 24 h. After 5 or 6 days of treatment, growth was assessed via MTT assay. Each well was added 60 μl of 5 mg/ml thiazolyl blue tetrazolium bromide solution (MTT) from Sigma-Aldrich in serum-free medium for 4 h at 37°C in dark. Media were aspirated and purple formazan crystals were lyzed with 500 μl of solubilization solution (95% dimethylsulfoxide and 5% Improved MEM). Absorbance was measured with a plate reader at 570 nm using a 650 nm differential filter to access growth. 
Soft agar assay

